OncLive TV

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Petros Grivas, MD, PhD, discusses the future of the phase 2 TROPHY U-01 trial regimen in metastatic urothelial cancer.

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.

Fady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.

Hao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Matthew Galsky, MD, discusses long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer.

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

Maher Albitar, MD, and Andre H. Goy, MD, discuss practical aspects of next-generation sequencing.

Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.

Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.

Matteo Lambertini, MD, discusses how GnRH agonists work to preserve ovarian function in premenopausal patients with breast cancer.

Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.